Compare Abbott Laboratories (ABT) vs Mercadolibre Inc (MELI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Mercadolibre Inc — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while Mercadolibre Inc trades at $1,791.6 (market cap $91.94B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays a 2.63% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| ABT | MELI | |
|---|---|---|
Market Cap | $166.94B | $91.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $2.51K |
52-Week Low | $82.57 | $1.55K |
Enterprise Value | $193.69B | $98.83B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
MercadoLibre (MELI) trades at $1,813.61, up 2.85% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with robust revenue growth of 49% in Q1 2026 and expanding cash flow generation. Analyst consensus remains strongly positive with a $2,230 price target, though margin compression from aggressive investments presents near-term challenges.
MELI offers significant growth potential as Latin America's e-commerce leader, but faces execution risks from margin pressure and legal investigations. The stock trades at premium valuations (P/E 47.66) requiring sustained high growth to justify current levels. Institutional support remains strong with 71.9% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
